Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$IMUN up 12.69%
Nice news! $SBEV more Walmart $WMT locations !
Name change coming!
4 years! Whoa .. you must have a big stack!
I disagree $BBRW going much higher
That's the $1,000,000 question .. right?
This baby is ready to pop up to .005 levels imho
L2 is a thing of beauty $SBEV
Churning through the 3's nicely here.
Great volume $BBRW
That's for sure $TNRG
Almost go time! $SBEV
No question about that resx18. Something big is about to go down here imo
Almost go time here $TNRG
Dave does a great job with the videos $TNRG
Looking for .02 break and hold $IMUN
$SBEV $IMUN $TNRG
O/S / public float
332,918,514
Oh here go with the conspiracy theories.
Starting to gain some momo here. Volume before PPS
Nice .. is that from the 8-K ?
Without question. That was an amazing deal for $IMUN
$IMUN and $NXGB here
$IMUN over .02
TapouT drink is huge too $SBEV
Big numbers #REVS $SBEV
$IMUN 8- K was awesome today
That wine is amazing! So easy to travel with it.
$SBEV is making moves .. going to up list soon imo
$IMUN $SBEV $TNRG
Ground floor opportunity here $SBEV
Bring on the up list! $SBEV
Salt Tequila in Walmart is the $$ maker imo $SBEV
TapouT is huge as well $SBEV
We are going to up list very soon imho $SBEV
Good Morning $TNRG
Pursuant to the sublicensing agreement, Cytocom will assume the following approximate obligations of the Company: $1,051,000 in accrued liabilities and accounts payable, $3,038,000 in notes and loans payable, and $1,111,000 in obligations owed to former Immune employees.
I like those numbers! $SBEV
Loaded a few today. $SBEV
Cytocom, Inc., a private clinical-stage biopharmaceutical company developing novel immune modulating therapies targeting cancer, autoimmune, inflammatory, and infectious diseases based on proprietary platforms, today announced the acquisition of ImQuest Life Sciences, Inc., a research and development company focused specifically on cancer, inflammation and infectious disease treatments, including its subsidiaries in an all-stock transaction.